Waypoint Capital Advisors LLC Has $1.26 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Waypoint Capital Advisors LLC boosted its holdings in shares of Danaher Co. (NYSE:DHR) by 0.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,520 shares of the conglomerate’s stock after buying an additional 42 shares during the period. Waypoint Capital Advisors LLC’s holdings in Danaher were worth $1,257,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Tsfg LLC lifted its position in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the 2nd quarter valued at approximately $25,000. nVerses Capital LLC purchased a new stake in Danaher in the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher during the 1st quarter valued at $30,000. Finally, MFA Wealth Advisors LLC purchased a new position in shares of Danaher during the 2nd quarter valued at $51,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Price Performance

Shares of Danaher stock opened at $274.38 on Friday. The firm has a fifty day moving average price of $270.72 and a two-hundred day moving average price of $260.02. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company has a market cap of $203.23 billion, a PE ratio of 46.51, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period last year, the business earned $2.05 earnings per share. Analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insiders Place Their Bets

In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Danaher news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock worth $11,042,433 over the last 90 days. Corporate insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on DHR. Barclays lifted their price objective on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 24th. Bank of America boosted their price target on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Evercore ISI lifted their target price on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Stifel Nicolaus increased their price target on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.